Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: ADXS

Three Companies with the Ingredients to Follow in the Footsteps of Advaxis (NASDAQ: ADXS)

WINDSOR, ON / ACCESSWIRE / June 16, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on the seldom huge potential of the OTC market when used as a proper stepping-stone to a national stock exchange.

Very seldom do you see long-term success in the sometimes scary OTC market. One might gauge long-term success as assembling a world class management team, raising some capital on not-so-good terms, and bringing a business plan to the point where it’s considered a valuable asset. Down this road, there are many more things that can go wrong than can go right. The proverbial pot of gold at the end of the rainbow would be the infamous “up-listing” to the NASDAQ or the NYSE-by way of achieving the aforementioned goals, but also quantifiable …

Continue Reading

Posted in Articles| Tagged , |

2-7-13 SmallCapVoice Interview with Advaxis Inc (ADXS)

Advaxis Inc (ADXS)
http://smallcapvoice.com/blog/wp-content/uploads/adxs-2-7-13.mp3

Chairman and CEO Thomas Moore of Advaxis, Inc (ADXS) called into SmallCapVoice.com to go over the business market, model and recent news for the company. Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.

ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & …

Continue Reading

Posted in Interviews| Tagged |